GALNT14
GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
Overview
Catalyses the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Displays activity toward mucin-derived peptide substrates such as Muc2, Muc5AC, Muc7, and Muc13 (-58). May be involved in O-glycosylation in kidney.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
- 1 · What it is
GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.
- 2 · What goes wrong in cancer
Catalyses the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.
- 3 · How drugs use it
No product in this corpus aims at GALNT14 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:22946 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96FL9 (protein name, function text, keywords and locations (REST API)); CIViC gene GALNT14 (1 evidence items, 0 assertions, 2 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0))
Biology
Catalyses the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Displays activity toward mucin-derived peptide substrates such as Muc2, Muc5AC, Muc7, and Muc13 (-58). May be involved in O-glycosylation in kidney. Location: Golgi apparatus membrane (UniProt). Locus 2p23.1 (HGNC).
- Hepatocellular carcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"GALNT14" OR ABSTRACT:"GALNT14" OR TITLE:"polypeptide N-acetylgalactosaminyltransferase 14" OR ABSTRACT:"polypeptide N-acetylgalactosaminyltransferase 14" OR TITLE:"Polypeptide N-acetylgalactosaminyltransferase 14" OR ABSTRACT:"Polypeptide N-acetylgalactosaminyltransferase 14" OR TITLE:"GalNac-T10" OR ABSTRACT:"GalNac-T10" OR TITLE:"FLJ12691" OR ABSTRACT:"FLJ12691" OR TITLE:"GalNac-T14" OR ABSTRACT:"GalNac-T14") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GALNT14, not a curated reading list.